Aclarion, Inc. (Nasdaq: ACON, ACONW) reported first quarter 2026 financial results on April 30, 2026, highlighted by a 196% year-over-year increase in Nociscan scan volumes and a 64% sequential increase from Q4 2025. The company attributed the growth to new account activation and deeper utilization within existing sites, signaling increasing integration of Nociscan into clinical workflows.
Nociscan is a SaaS platform that uses magnetic resonance spectroscopy and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain. With approximately 5.8 million lumbar MRIs performed annually in the U.S. for low back pain, Aclarion believes the addressable market represents a potential $2 billion opportunity.
Several catalysts are driving growth. Nociscan has been reimbursed by Vitality, AXA, and Aviva—three of the four largest private insurers in the U.K.—providing validation and a pathway for broader coverage. Aclarion also launched a targeted direct-to-patient campaign in the U.K., featuring a video with Mr. John Sutcliffe, Consultant Spinal Neurosurgeon at The London Clinic. The video is available here. In the U.S., the company continues to engage payers through its Nociscan Reimbursement Program.
On the clinical front, Aclarion is advancing the CLARITY randomized trial, with a preliminary internal readout expected in the second half of 2026 and public disclosure of early interim results anticipated in late 2026. Seven ongoing clinical trials and multiple investigator-initiated real-world evidence trials are underway to support reimbursement discussions and potential local coverage decisions by commercial insurers.
The company strengthened its intellectual property portfolio with a newly issued patent covering the use of AI in workflows of future products. Aclarion now holds 64 issued and pending patents worldwide. Financially, the company reported $19.0 million in cash as of March 31, 2026, with no debt. Management believes existing cash resources, combined with a $2.5 million share repurchase program announced this week, are sufficient to fund operations into the second half of 2027.
"Q1 represents a clear inflection for Aclarion," said Brent Ness, Chief Executive Officer. "Scan volume growth accelerated significantly, driven by increasing physician adoption and stronger execution. Importantly, we are still in the early stages of commercializing Nociscan into a large and underpenetrated market."
